Skip to main content
Caplight Logo









Alltrna

Alltrna

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.alltrna.com/

Last Round

Series B

Aug 9, 2023

Total Funding Raised

$159M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Alltrna is a biotechnology company that develops a tRNA-based therapeutic platform leveraging artificial intelligence and machine learning to advance programmable medicines for genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

tRNA therapeuticsstop codon diseaseRNA therapeuticsgenetic medicineRNA medicinebiotech platformdrug discoveryclinical-stage biotechrare diseaseAI-driven drug discoverycomputational biologyprogrammable therapeuticsprotein restorationbiotech startupnext-gen biologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alltrna Comparables

Compare Alltrna with similar companies based on industry and business-model similarity.

Alltrna comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tevard Biosciences
88%
Codone Biotechnology
85%
Shape Therapeutics
83%

Alltrna Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 9, 2023
SeedNov 9, 2021

Key People

Founding team and executive leadership

Lovisa Afzelius

Founding CEO Chair Of The Board

Founding Team

Michelle Werner

Chief Executive Officer

Executive Team

Alltrna Investors

Notable investors and investment history

Alltrna investors
InvestorRounds
Flagship PioneeringFounding, Seed, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Lead program AP003 is a tRNA oligonucleotide for Stop Codon Disease.

  • Sep 3, 2025

    David Hava appointed to lead tRNA medicines pipeline strategy.

Alltrna Filings

Explore SEC and related filing metadata, where available.

Alltrna filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Alltrna's valuation, stock price, and market status.

Is Alltrna a public or private company?

Alltrna is a private company.

What is the current stock price of Alltrna?

Alltrna is a private company, so its shares have no public market price. Caplight tracks Alltrna's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Alltrna worth (valuation)?

Valuation information for Alltrna is not publicly available.

Can I buy Alltrna stock?

Alltrna shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Alltrna's last funding round?

Alltrna's most recent funding round was Series B on August 9, 2023.

Who are the main investors in Alltrna?

Key investors in Alltrna include Flagship Pioneering.

Will Alltrna IPO soon?

No public IPO plans have been announced for Alltrna.

How can I track Alltrna secondary market activity?

Caplight tracks bids, offers, and trades in Alltrna's shares on secondary markets.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range45
Year Founded2018
Last FundingAug 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?